UNIVERSITY OF UTAH RESEARCHERS DEVELOP FASTER, MORE ACCURATE TEST FOR LIVER CANCER THAT CAN BE ADMINISTERED ANYWHERE
It’s estimated that about 788,000 people worldwide died of liver cancer in 2015, the second-leading cause of cancer deaths, according to the latest statistics from the World Health Organization. One of the major challenges in combatting this disease is detecting it early because symptoms often don’t appear until later stages.
But a team of researchers led by University of Utah chemical engineering and chemistry professor Marc Porter and U surgeon and professor Courtney Scaife has developed a rapid portable screening test for liver cancer (hepatocellular carcinoma) that doesn’t involve sending a specimen to a blood lab and cuts the wait time for results from two weeks to two minutes. This new and inexpensive test — the team is working to lower the cost to about $3 per test — can be administered wherever the patient is, which will be particularly valuable in developing nations with little access to hospitals.
The test uses a small domino-sized plastic cartridge containing a paper membrane that selectively traps biomarkers (proteins specific to a certain disease) from biological fluids. A small droplet of blood, saliva, or urine, or even a teardrop, from the patient is dropped onto the membrane. This is followed by the droplet of gold nanoparticles, which tags the biomarkers trapped in the membrane. If the biomarkers are present, a red spot appears, signaling the patient has the disease and should seek more testing and possible treatment.
“The concept is similar to a home pregnancy test, but instead of flowing laterally, it flows through the membrane,” says Granger, the lead author on the paper.
A handheld spectrometer manufactured by project collaborator B&W Tek, a Delaware-based manufacturer of mobile spectrometers, can analyze the membranes and measure how much of the biomarkers is present, which in the future could determine the severity of the disease or how a patient is responding to treatment.
The idea for the test is a spinoff of a similar test Porter developed eight years ago that astronauts on the International Space Station used to test the cleanliness of their drinking water. “This is a smarter offshoot of that,” says Porter, who also is the director of the Nano Institute of Utah.
Now that the team has proven the concept with liver cancer and built a prototype test kit, researchers plan to evaluate the technology in Mongolia in spring of 2019. The East Asian country has the highest rate of liver cancer in the world.
The project was funded by grants from the National Institutes of Health, the National Cancer Institute through the Affordable Cancer Technologies Program and the Huntsman Cancer Institute. The team also received funding from Utah-based nutritional supplement company USANA which is interested in using a form of the test for customers with certain vitamin deficiencies.
“USANA has a keen interest in the ability to measure certain vitamins and biomarkers in various bodily fluids that can be related to a person’s health status,” said Mark Brown, Executive Director of Laboratory Sciences at USANA. “This would allow our customers to see for themselves the benefit of taking USANA’s high quality products. Rather than taking a blood sample and sending it off to lab for analysis, this technology could make it possible for people to do their own analysis in the comfort of their own home. Small sample size and simplicity of use are crucial components of making this a reality, and this research is a step closer to that end.”
Learn more: PUTTING IT TO THE TEST
The Latest on: Liver cancer
- Study reveals the effect of ancestry on molecular makeup of canceron May 11, 2020 at 7:01 pm
Questions about the genealogical imprint of tumors have hovered over cancer research since the completion of the Human Genome Project in 2003.
- A connection between ancestry and the molecular makeup of canceron May 11, 2020 at 3:29 pm
Questions about the genealogical imprint of tumors have hovered over cancer research since the completion of the Human Genome Project in 2003. Is liver ...
- Lipid-encapsulated siRNA for hepatocyte-directed treatment of advanced liver diseaseon May 11, 2020 at 12:43 pm
LNPs have been specifically tested for hepatocyte delivery of siRNA molecules, since the liver is a well-perfused organ with a fenestrated endothelium. On the other hand, LNPs are known to interact ...
- Racial Inequalities of Liver Cancer Mortality Increase After Introduction of Hepatitis C Drugson May 11, 2020 at 11:18 am
Racial inequalities of the mortality rate from liver cancer in the United States steadily increased from 1998-2016 after the introduction of lifesaving drugs for the hepatitis C virus in 1998, ...
- Mapping the cancer connectionon May 11, 2020 at 8:00 am
A new study takes the most comprehensive look to date at the connection between the ancestry and the molecular makeup of cancer.
- Liver Cancer Therapeutics Market is expected to expand at the highest cagr By 2025 : ArQule, Bayer, Bristol-Myers Squibb, Celsionon May 11, 2020 at 3:52 am
The market report based on our unique research methodology delivers thorough analytical scrutiny of the Liver Cancer Therapeutics Market dispersed across several segments. The report also consists of ...
- Study Links Drugs for Hepatitis C to Racial Inequalities in Liver Cancer Mortalityon May 4, 2020 at 12:59 pm
Although lifesaving drugs became available around 1998 to treat hepatitis C, they were expensive, which limited access for some patients.
- Oncogenic driver genes and tumor microenvironment determine the type of liver canceron May 4, 2020 at 5:39 am
Primary liver cancer (PLC) may be mainly classified as the following four types: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), hepatoblastoma (HB), and combined hepatocellular ...
- Liver cancer surge in Scotlandon May 4, 2020 at 3:14 am
A significant increase in live cancer in Scotland has been reported. Scottish charity Worldwide Cancer Research, has committed £430,000 of extra funding into liver cancer research over the next three ...
- Racial inequalities in liver cancer mortality increased after introduction of hepatitis C drugson April 30, 2020 at 10:58 pm
In the United States, hepatocellular or liver cancer deaths have doubled since 1979. Hepatitis C virus is the leading cause of liver cancer.
via Google News and Bing News